Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.09Last Year’s EPS
-0.5Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 04, 2025
|% Change Since: -19.02%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong year for Rigel Pharmaceuticals, marked by record-breaking sales, successful product integration, and global expansion. Despite some reliance on inventory build and pending decisions on study designs, the company's achievements in financial performance and R&D progress contribute to a predominantly positive outlook.Company Guidance
During the Rigel Pharmaceuticals financial conference call for the fourth quarter and full year 2024, key guidance was provided concerning their financial and strategic outlook. The company reported a record high in commercial portfolio sales of $145 million for 2024, marking a 39% increase from the previous year, driven by products like TAVALISSE, Rezlidia, and the newly added Gavreto. Rigel Pharmaceuticals achieved profitability for the first time with a full-year net income of $17 million and increased their cash balance by over $20 million. For 2025, they project net product sales between $185 million and $192 million, representing a 28% to 32% growth. They also anticipate achieving total revenue between $200 million and $210 million, with continued positive net income while funding existing and new clinical development programs. The company plans to advance its pipeline with ongoing Phase 1b studies and strategic collaborations, aiming to maintain financial discipline throughout 2025.Record Sales Growth
Rigel Pharmaceuticals achieved its highest commercial portfolio sales ever in 2024, reaching $145 million, representing a 39% growth over 2023.
Introduction of Gavreto
Gavreto, added to the portfolio in June 2024, contributed $17.1 million in net product sales, illustrating a successful transition and integration into Rigel's offerings.
Global Expansion
TAVALISSE received regulatory approvals in Mexico and the Republic of Korea, expanding its global footprint. Additionally, new licensing agreements for Rezlidia were executed in Asia and Latin America.
R&D Progress
Significant progress in the development pipeline, particularly with R289, which showed promising safety and efficacy in a Phase 1b study for lower-risk MDS.
Financial Milestones
The company reported its first full-year net income of $17 million, with a cash balance increase of over $20 million, indicating strong financial discipline.
---
RIGL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RIGL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 04, 2025 | $22.08 | $20.29 | -8.11% |
| Nov 07, 2024 | $15.44 | $22.07 | +42.94% |
| Aug 06, 2024 | $9.33 | $9.87 | +5.79% |
| May 07, 2024 | $11.90 | $9.92 | -16.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Rigel (RIGL) report earnings?
Rigel (RIGL) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is Rigel (RIGL) earnings time?
Rigel (RIGL) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RIGL EPS forecast?
RIGL EPS forecast for the fiscal quarter 2025 (Q1) is 0.09.
---